

Our Ref.: 427.010-1-DIV-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:

Serial No.: 09/612,382

DENNIS BIGG et al

Patent No.: 6,797,715 (3)

Filed: July 7, 2000

Issued: September 28, 2004

For: NEW...CONTAINING THEM

475 Park Avenue South New York, N.Y. 10016 November 10, 2004

## REQUEST FOR CERTIFICATE OF CORRECTION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Certificate NOV 1 6 2004

of Correction

Sir:

Patentees are submitting herewith a request for a certificate of correction to correct the structural formula in claim 1 which has a methyl in the 3-position which is improper as can be seen from a reading of the claim and from the formula of claim 18, a copy of which is enclosed herewith. There is no substitution in this position in the formula. The claim calls for an unsubtituted or a pharmaceutically acceptable substituted camptothecin with a 7-ring member beta hydroxyl lactone. There was an error in the printing of the same and therefore, no fee is required.

> Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683

Attorney for Patentees Tel.# (212) 661-8000

CAM:ds Enclosures

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 6,797,715 🗗

DATED

: 09/28/04

INVENTOR(S): DENNIS BIGG et al

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please replace the formula at the top of column 93, claim 1, with the following formula:

MAILING ADDRESS OF SENDER:

PATENT NO. 6,797,715 1

Muserlian, Lucas and Mercanti 475 Park Avenue South New York, N.Y. 10016

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Also Form PTO-1050)

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 6,797,715**(**5)

DATED

: 09/28/04

INVENTOR(S): DENNIS BIGG et al

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please replace the formula at the top of column 93, claim 1, with the following formula:

MAILING ADDRESS OF SENDER:

Muserlian, Lucas and Mercanti 475 Park Avenue South New York, N.Y. 10016

PATENT NO. 6,797,715 (6)

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

- (+)-1-[9-chloro-5-ethyl-5-hydroxy-10-methyl-3,15-dioxo-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinolin-12-ylmethyl]4-methyl-hexahydropyridine;

or a pharmaceutically acceptable salt of the latter.

18. The method of treating a cancer selected from the group consisting of leukemia, colon cancer, lung cancer, prostate and breast cancer in warm-blooded animals comprising administering to warm-blooded animals in need thereof a unsubstituted or pharmaceutically acceptable substituted camptothecin with a 7-ring member β-hydroxy lactone ring of the formula

wherein R<sub>1</sub> is selected from the group consisting of alkyl of 1 to 6 carbon atoms, alkenyl and alkynyl of 2 to 6 carbon atoms haloalkyl of 1 to 6 carbon atoms, alkoxy alkyl of 2 to 12 carbon atoms and alkylthioalkyl of 2 to 12 carbon atoms. R<sub>p</sub> is hydrogen or an easily cleavable group, R<sub>18</sub> and R<sub>19</sub> are individually selected from the group consisting of hydrogen, halogen. OH and alkyl and alkoxy of 1 to 6 carbon atoms and its non-toxic, pharmaceutically acceptable salts.